The ADAM study continued: maintenance therapy after 50 weeks of induction therapy

AIDS. 2001 Jan 5;15(1):129-31. doi: 10.1097/00002030-200101050-00022.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Drug Administration Schedule
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1* / genetics
  • Humans
  • Lamivudine / therapeutic use
  • Nelfinavir / therapeutic use
  • RNA, Viral / blood
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Saquinavir / therapeutic use
  • Stavudine / therapeutic use
  • Time Factors
  • Treatment Outcome
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Stavudine
  • Nelfinavir
  • Saquinavir